[en] Both obesity and type 2 diabetes (T2D) are recognized risk factors for developing a more severe form of COVID-19, with a higher death rate. Metformin is considered as the first-line medication for the treatment of T2D, especially in obese patients. Beyond its glucose-lowering activity, metformin exerts pleiotropic effects, among which an anti-inflammatory effect that could be beneficial. However, metformin is contraindicated in case of severe renal insufficiency, liver failure and/or unstable heart failure, because of a risk of lactic acidosis. Yet, COVID-19, besides the well-known pneumonia that can be responsible for severe hypoxemia, may be associated with multisystemic organ failure, among which kidneys, liver and heart. Thus, the question arises whether metformin, which represents the background therapy in above 80 % of patients with T2D, should be continued in patients exposed to SARS-CoV-2 or instead be stopped. This article summarizes the most important results of observational studies, which all argue for a beneficial effect of metformin therapy that is associated with a significant reduction in mortality among hospitalized patients with T2D due to COVID-19. Finally, some practical advices will be given.
Davenne E, Giot JB, Huynen P. Coronavirus et COVID-19: le point sur une pandémie galopante. Rev Med Liege 2020;75:218-25.
Scheen AJ. Editorial. SARS-CoV-2 et COVID-19: pas au bout des doutes, questionnements et controverses. Rev Med Liege 2020;75:1-5.
Marchetta S, Lambermont B, Massion P, et al. La première vague du COVID-19 aux Soins Intensifs. Mars-Mai 2020. Rev Med Liege 2020;75:18-28.
Vas P, Hopkins D, Feher MD, et al. Diabetes, obesity and COVID-19: a complex interplay. Diabetes Obes Metab 2020;22:1892-6.
De Flines J, Scheen AJ. COVID-19 sévère, une nouvelle complication à ajouter aux nombreuses comorbidités de l’obésité. Rev Med Liege 2020;75:146-52.
Paquot N, Radermecker RP. COVID-19 et diabète. Rev Med Liege 2020;75:138-45.
Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and recent reports. Diabetes Metab 2020;46:265-71.
Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63:1500-15.
Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet. Diabetes Endocrinol 2020;8:782-92.
Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract 2020;163:108146.
Scheen AJ, Paquot N. Prise en charge de l’hyperglycémie du diabète de type 2: changement de paradigme selon le consensus ADA-EASD 2018. Rev Med Liege 2018;73:629-33.
Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2. Rev Med Liege 2020;75:233-9.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179-90.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60:1577-85.
Cameron AR, Morrison VL, Levin D, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 2016;119:652-65.
Scheen AJ. Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes Metab 2020;46:423-6.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020;318:E736-E41.
Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 2017;19:473-81.
Ma C, Cong Y, Zhang H. COVID-19 and the digestive system. Am J Gastroenterol 2020;115:1003-6.
Lalau JD, Kajbaf F, Protti A, et al. Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab 2017;19:1502-12.
Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31.
Erpicum P, Grosch S, Bouquegneau A, et al. Atteintes rénales de la COVID-19. Rev Med Liege 2020;75:109-14.
Haeck G, Ancion A, Marechal P, et al. COVID-19 et maladies cardiovasculaires. Rev Med Liege 2020;75:226-32.
Ursini F, Ciaffi J, Landini MP, et al. COVID-19 and diabetes: is metformin a friend or foe? Diabetes Res Clin Pract 2020;164:108167.
Lui DTW, Tan KCB. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes? J Diabetes Investig 2020;doi:0.1111/jdi.13484.
Lukito AA, Pranata R, Henrina J, et al. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:2177-83.
Lalau JD, Al-Salameh A, Hadjadj S, et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab 2020;101216.
Scheen AJ. Comment je traite... par metformine un patient diabétique avec insuffisance rénale modérée. Rev Med Liege 2013;68:190-5.
Scheen AJ, Lefèbvre PJ, Paquot N. La metformine revisitée: moins de restrictions et davantage d’indications. Rev Med Liege 2018;73:544-9.
Scheen AJ, Paquot N. Utilisation de la metformine chez le patient diabétique cardiaque: balance bénéfices-risques. Rev Med Suisse 2013;9:1527-33.
Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab 2020;101220.
Krzesinski JM, Scheen AJ. Importance d’interrompre certains médicaments en cas de troubles digestifs et de déshydratation. Rev Med Liege 2017;72:266-71.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.